Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG-92505
- Development stage
- Phase 1
- Lead developer
- BeOne Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BG-92505 is an orally administered small molecule modulator of the KEAP1-NRF2 pathway, developed by BeOne Medicines (formerly BeiGene) for the treatment of advanced solid tumors. It acts by activating Kelch-like ECH-associated protein 1 (KEAP1), which promotes the degradation of nuclear factor erythroid 2-related factor 2 (NRF2). NRF2 is a transcription factor that is often hyperactivated in cancer cells, promoting cell survival, growth, and resistance to therapy. By facilitating KEAP1-mediated degradation of NRF2, BG-92505 aims to suppress tumor growth and overcome treatment resistance. It is currently being evaluated in a Phase 1 clinical trial as a monotherapy and in combination with other antineoplastic agents in patients with advanced solid tumors.
- Other names
- BG-92505片
02
Targets
CUL3 (Cullin-3)KEAP1 (Kelch-like ECH-associated protein 1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on BG-92505.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BG-92505.